Objective To investigate potential differences in the availability of medicines for chronic and acute conditions in low-and middle-income countries.
Introduction
Chronic, noncommunicable diseases such as cardiovascular diseases, diabetes and asthma impose a large and growing health burden on developing countries. 1 Chronic diseases are responsible for at least 50% of the deaths that occur in all World Health Organization (WHO) regions except Africa, where they still account for 25% of all deaths. While the proportion of deaths from chronic diseases is largest in high-income countries, in lowand middle-income countries chronic diseases continue to cause 39% and 72% of all deaths, respectively. 2 Cardiovascular diseases alone account for 30% of all deaths in the world, 2 80% of which occur in low-and middle-income countries. 1 It has been estimated that an additional reduction of 2% annually in deaths from chronic conditions would avert 28 million deaths in low-and middle-income countries between 2005 and 2015. 3 Chronic conditions also cause substantial morbidity in terms of disability-adjusted life years (DALYs), a measure of the potential life lost due to premature mortality and of the productive life lost due to disability. Chronic conditions account for one third of DALYs in low-income countries and for nearly two thirds in middle-income countries. 2 In Africa, where chronic disease morbidity is lowest, these conditions still account for 21% of DALYs.
Developing countries undergoing an epidemiological transition from infectious and parasitic diseases to chronic diseases require health systems modifications to address the long-term nature of chronic conditions, in addition to prevention efforts. The WHO
Action Plan for the Global Strategy for the Prevention and Control of Noncommunicable
Diseases recommends addressing management in the context of overall health system strengthening. 4 Continuous access to essential medicines, with an emphasis on rational selection, affordable prices and sustainable financing, should be a key component of the policy framework. 1 Appropriate pharmacological treatment has been shown to significantly reduce morbidity and mortality from chronic conditions, 5-9 yet the necessary medicines are not equitably distributed or used as widely as required. 3 Several studies have found that low drug availability limits access to medicines in low-and middle-income countries. [10] [11] [12] [13] [14] [15] [16] [17] [18] 
Methods

Data source
Data were obtained from drug price and availability surveys conducted using a standard, validated methodology developed by WHO and Health Action International (HAI). [26] [27] [28] In the survey, the availability of 50 medicines was investigated through visits to public and private sector facilities. Data were collected on standard medicines that enable international comparisons and on medicines selected by each country for their importance nationally (e.g. drugs for high-burden diseases). Availability was determined for: (i) the originator brand first authorized worldwide for marketing (normally as a patented product) on the basis of the documentation of its efficacy, safety and quality, according to requirements at the time of authorization; and (ii) generic equivalents intended to be interchangeable with the originator brand product. Availability is reported as the percentage of facilities where a product was found on the day of data collection. The difference or gap in availability was calculated by subtracting the availability of medicines for chronic conditions from the availability of medicines for acute conditions.
Survey inclusion
All surveys conducted following the WHO/HAI method and included in the HAI database 29 on 24 September 2009 were considered for inclusion, with the exception of nine pilot surveys that measured availability using different methods. In countries where repeat surveys were conducted, the most recent data set was used. In countries where multiple surveys were conducted at the state/provincial level, results were averaged were included in the analysis, yielding a sample of 2779 medicine outlets (Table 1) .
Medicine selection
Any medicine covered in at least one survey was considered for inclusion and was classified as being for either acute or chronic treatment according to its primary indication for use. In accordance with methods published previously, 11 the 15 medicines most frequently covered in WHO/HAI surveys for acute and chronic conditions were included in the analysis to maximize the comparability of data across countries. Such medicines are effective based on the evidence, are used to treat high-burden conditions and are widely used internationally.
26,27
Data analysis
The per cent availability of each medicine was extracted for both originator brand and generic products in both the public and private sectors. When alternate strengths of the same medicine were included in a survey, the availability of each of the two strengths was combined on a facility-by-facility basis to determine the overall availability of the medicine. Alternate strengths were only combined when used for the same indication; adult and paediatric dosage forms were kept separate.
Availability was analysed for: (i) the originator brand, (ii) the generic equivalent and (iii) any product (brand or generic). For the last category, the availability of originator brands and generics was combined on a facility-by-facility basis to determine the overall availability of each medicine.
The mean availability of each basket of medicines (for acute and chronic conditions) was calculated and, as data were normally distributed, the unpaired t-test was used to test the difference in mean availability between baskets. As availability was measured in the same facilities in each country, confounding factors such as facility type and location were eliminated. To investigate whether the availability of medicines for chronic conditions differed by indication, the mean availability of each therapeutic class represented in this medicines basket was calculated and compared with the mean availability of the 15 medicines in the acute conditions basket. Results Table 2 shows the 30 medicines included in the analysis. In the basket of medicines used to treat acute conditions, the frequency with which individual medicines were included in WHO/HAI surveys ranged from 24% to 100%; in the basket of medicines for chronic conditions, it ranged from 72% to 100%. This is not an indication of medicine availability In the public sector, the mean availability of generic medicines was low for both baskets: 53.5% for medicines for acute conditions and 36.0% for medicines for chronic conditions, with medicines for acute conditions significantly more available (P = 0.001) (Table 3) . Originator brands of medicines in both the acute and chronic condition baskets were rarely available in the public sector. When product types were combined to yield the availability of any given product (originator brand or generic) at each facility, the difference in availability between the two baskets (14.3%) remained statistically significant (P = 0.009).
In the private sector, the mean availability of generics in each basket was higher than in the public sector (66.2% for generics for acute conditions and 54.7% for generics for chronic conditions), but it was still low. The availability of generic products differed significantly between the two baskets (11.5%; P = 0.007), but the availability of originator brands was the same (39.1%). The difference in the availability of any product type (originator or generic) was 5.6% (P = 0.070).
When the availability of medicines for chronic conditions was disaggregated by therapeutic classes, in both the public and the private sector antiulcerants and antidiabetics were the drugs most widely available for the chronic indications studied, with availability comparable to that of the basket of medicines for acute indications ( Fig. 1 ). In fact, in the private sector the average availability of antiulcerants was higher than that of the 15 medicines for acute conditions. Antihypertensives and cardiovascular medicines had the next highest availability among the drugs for chronic indications, but their availability was 8.5% and 21.4% lower than that of medicines for acute conditions in the private and the public sectors, respectively. Antiasthmatics, antiepileptics and antidepressants had similarly low availability (28-30% and 40-45% in the public and private sectors, respectively) and showed the largest difference in availability with respect to the acute conditions basket. The availability of individual medicines in the countries studied can be obtained from the corresponding author upon request.
Mean differences in the per cent availability of the baskets of medicines for acute and chronic conditions in each country are shown by World Bank income group (Fig. 2) and WHO region (Fig. 3 ). Fig. 2 shows an inverse relationship between income level and the gap in availability between medicines for acute and chronic conditions, particularly in the public sector. In low-and lower-middle-income countries, the mean differences in availability were 33.9% and 12.9%, respectively, while in upper-middle-income countries the availability was nearly equal and in high-income countries medicines for chronic conditions had higher availability. In the private sector the availability gap was smaller than in the public sector in all country income groups. No relationship was found in the (data available from the corresponding author upon request).
The African region showed a substantially larger average difference (nearly 40%) than other regions in the availability of medicines for acute and chronic conditions in the public sector (Fig. 3) . In the South-East Asia Region, the Region of the Americas and the Eastern Mediterranean Region, medicines for acute conditions were 4% to 14% more available in the public sector, on average, than those for chronic conditions, while in the European Region and the Western Pacific Region medicines for chronic conditions were somewhat more available than those for acute conditions in the public sector. In the private sector, the African region again showed the largest difference in availability between medicines for acute and for chronic conditions (16.7%), but this difference was less pronounced than in the public sector. In the Region of the Americas, the European
Region and the South-East Asia Region, medicines for acute conditions were more available than those for chronic conditions in the private sector, while in the Eastern Mediterranean Region two medicine baskets had comparable availability and in the Western Pacific Region medicines for chronic conditions were more available than those for acute conditions.
Discussion
The WHO has set a benchmark of 80% for medicine availability, 33 against which the values found in this study were sub-optimal for both the acute and chronic condition medicine baskets, particularly in the public sector. Low public sector availability can result from factors such as inadequate funding, lack of incentives for maintaining stocks, inability to forecast needs accurately, inefficient purchasing/distribution systems or leakage of medicines for private resale. 11 The low availability of medicines in the public sector is a general problem, and this study shows that medicines for chronic conditions are even less available than medicines for acute conditions, particularly in low-and lower-middle-income countries. This may be the result of government policies that do not provide for widespread access to medicines for chronic conditions through the public The difference in availability between the two medicine categories was consistently smaller in the private sector than in the public sector (11.5% versus 17.5%).
This suggests that the current demand for medicines for chronic conditions exceeds what the public sector is providing and that low demand resulting from low diagnostic rates or other factors does not account for the low availability observed in the public sector.
However, the availability of generics in the private sector was still low and probably not enough to compensate for the lack of availability in the public sector. Further, in the private sector, medicines for chronic conditions usually cost substantially more than in the public sector and are often unaffordable. 11, [19] [20] [21] [22] [23] [24] [25] 34 Chronic disease patients, who need lifelong treatment, may find these medicines even less affordable than other patients. In developing countries, catastrophic health spending (e.g. spending on drugs and health care in excess of 40% of the income remaining after meeting subsistence needs) is common. 35 Health policies should therefore be designed to protect people from these expenditures by increasing financial risk protection through health insurance schemes that cover essential medicines for outpatients, including drugs for chronic conditions. The cost of medicines to both patients and health systems can also be reduced by promoting quality-assured, low-cost generic medicines through preferential registration procedures, financial incentives for prescribing and dispensing generics, generic substitution and measures to heighten trust among physicians, pharmacists and patients in the quality of generics.
11
In both the public and private sectors, antiasthmatics, antiepileptics and antidepressants, and antihypertensives to a lesser extent, were the drivers of the gaps in the availability of drugs in the acute and chronic condition baskets (Fig. 1) . However, as previously reported, 19 in some therapeutic classes (e.g. antidiabetics and antihypertensives) substantial variation was observed in the availability of individual medicines. Results may also have been influenced by the treatment options included in each class. For example, the availability of antidiabetics may have been influenced by the exclusion of insulin, whose availability was low in a previous study.our findings is supported by the fact that the therapeutic classes with the highest to lowest availability followed the same pattern in both the public and private sectors.
As the income level of a country decreases, the difference in availability between medicines for acute and chronic conditions increases, particularly in the public sector (Fig. 2) . Priority should therefore be given to improving the availability of medicines for chronic conditions in low-and lower-middle-income countries, where the availability gaps are largest. According to a similar analysis by WHO region, the availability of the two treatment types differs most widely in countries in the African Region (Fig. 3) . Since 25% of all deaths in Africa are caused by chronic conditions, current disease patterns do not explain the observed gap. Disease patterns vary by individual country, but the medicines in this study are used to treat very common chronic conditions and should be available in sufficient quantities in any health system.
This analysis improves upon a previous analysis of medicine availability based on data from WHO/HAI surveys 11 in that alternate strengths of the same medicine were combined to account for country-level differences in medicine use. However, availability data only apply to the day of data collection and may not reflect average availability over time. Nevertheless, the data were collected in at least 20 facilities per country using a validated sampling frame 28 and therefore provide a reasonable estimate of the overall situation. Further, the analysis is more concerned with the relative availability of medicines used for acute and chronic conditions than with their absolute availability.
Another limitation is that the availability of individual medicines in the public sector may be influenced by whether or not they are on the national essential medicines list (a government-approved selective list used for procurement or reimbursement) and by the level(s) of care for which they are expected to be available.
The choice of medicines for the secondary analysis, which was restricted to the medicines included in WHO/HAI surveys, may also have limited the results. These surveys comprise both common medicine formulations that enable international comparisons and medicines of national importance, which are selected in accordance with disease burden, medicine usage patterns and recommendations in standard treatment guidelines. The selection process for survey medicines is described in detail consumption data were used to analyse the medicines surveyed and those recommended for chronic conditions were found to be widely used worldwide. 27 However, a further limitation is that the lack of a clear distinction between acute and chronic indications for some medicines that are used intermittently over long time periods (e.g. antimalarials)
and for medicines used to treat acute episodes of chronic disease (e.g. diazepam). In addition, while all of the medicines studied are off patent, the date of patent expiry may have affected the availability of multisource generic products on the market. Certain products, such as omeprazole, losartan, ciprofloxacin and fluconazole, have been off patent for less than 10 years and the persistence of the originator brand product following patent expiry may have reduced the availability of generics of these products.
Despite these limitations, this study raises important concerns about access to treatment for the millions of people with chronic conditions who live in developing countries. Governments should prioritize the supply of medicines for chronic conditions through their public health systems to ensure that people have access to the treatment they need. Low availability in the public sector can be through improved procurement efficiency and supply chain management as well as adequate, equitable and sustainable financing. In practice this could mean implementing schemes to make medicines for chronic conditions available through the private sector at no cost or at subsidized prices, as is done in Jamaica and in Trinidad and Tobago 36, 37 . International financing can also strongly affect public sector availability. In Kenya, for example, the availability of the Malaria. 16 While this study addresses the supply-side barriers to access to treatment for chronic conditions, efforts to address demand-side issues are also required. Supply that remains on the shelf is of little use; conversely, stimulating demand makes no sense if there is no supply. The extent to which a low demand for medicines for chronic conditions affects their availability is outside the scope of this analysis and warrants further investigation. However, our analysis suggests that current demand outweighs supply in the public sector and that no efforts should be made to further increase demand unless an adequate and ongoing supply of medicines can be ensured.
Successes in scaling-up treatment for HIV infection can offer lessons in connection with other chronic conditions. For example, HIV/AIDS treatment programmes in sub-Saharan Africa have shown relatively high patient adherence (77%)
to complex antiretroviral regimens. 38 Ensuring sustained medicine availability is clearly an essential precondition to achieving high adherence rates. Success in the field of HIV/AIDS stems largely from global and national efforts in the areas of mobilization and advocacy, financing and engagement of civil society. 39 Alongside current efforts in connection with communicable diseases, international agencies, governments and other stakeholders should work together to raise the profile of chronic diseases on health and development agendas and to advocate for a balanced approach that addresses both prevention and treatment.
To date, the control of chronic diseases in developing countries has received little international attention. 3, 40 The UN Summit on Non-communicable Diseases to be held in September 2011 is a positive step towards recognizing the importance of chronic diseases on the global health agenda. Our study shows that reorienting and strengthening health systems to enable a more effective and equitable response to chronic diseases should be a key priority, as recommended in the WHO Action Plan for the Global Strategy for the Prevention and Control of Chronic Diseases. Target 8.E of the Millennium Development
Goals deals with access to affordable essential medicines in developing countries. 10, 12, 16 To achieve this target, special efforts will be required to ensure universal and sustained availability of medicines for chronic conditions. 
Conclusion
Although the disease burden from chronic conditions in developing countries is large, wide gaps exist in the availability of medicines for chronic conditions. This study shows that such medicines are less available than those for acute conditions, which have traditionally been the focus of health systems in these countries. To ensure equitable access to treatment for different types of diseases, greater national and international attention should be given to chronic disease control, including access to medicines. b Availability is expressed as the percentage of facilities where a product was found on the day of data collection.
c The values represent the mean availability of medicines for acute conditions minus the mean availability of medicines for chronic conditions.
d The availability of originator brands in the public sector was 0% in several countries. This skewed the data and prevented the calculation of statistical significance. A n t i u l c e r a n t s 
